NetIncomeLoss YoY
-112%
Quarter · Through 30 Jun 2023
Tengjun Biotechnology Corp. financial metrics
Period Q2 2023 · Filed 15 Aug 2023
Key metrics snapshot
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| NetIncomeLoss YoY |
-112%
Quarter · 30 Jun 2023
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
100,711,196
Period-end balance · 10 Aug 2023
|
+12% |
| Common Stock, Shares, Outstanding |
100,711,196
Period-end balance · 30 Jun 2023
|
+54% |
| Common Stock, Value, Issued |
$100,711
Period-end balance · 30 Jun 2023
|
+54% |
| Weighted Average Number of Shares Outstanding, Basic |
100,187,364
Reported period · 30 Jun 2023
|
+53% |
| Weighted Average Number of Shares Outstanding, Diluted |
100,187,364
Reported period · 30 Jun 2023
|
+53% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accumulated Other Comprehensive Income (Loss), Net of Tax |
$2,302,142
Period-end balance · 30 Jun 2023
|
-939% |
| Additional Paid in Capital |
$8,988,779
Period-end balance · 30 Jun 2023
|
+717% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$25,112,151
Period-end balance · 30 Jun 2023
|
+271% |
| Common Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Jun 2023
|
0% |
| Common Stock, Shares Authorized |
200,000,000
Period-end balance · 30 Jun 2023
|
0% |
| Common Stock, Shares, Issued |
100,711,196
Period-end balance · 30 Jun 2023
|
+54% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent |
$5,035,938
Trailing 12 months · 30 Jun 2023
|
+36% |
| Deferred Tax Assets, Valuation Allowance |
$100,000
Period-end balance · 30 Jun 2023
|
|
| Earnings Per Share, Basic |
0
Reported period · 30 Jun 2023
|
-100% |
| Earnings Per Share, Diluted |
0
Reported period · 30 Jun 2023
|
-100% |
| General and Administrative Expense |
$417,334
Reported period · 30 Jun 2023
|
+55% |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest |
$468,964
Reported period · 30 Jun 2023
|
-110% |
| Income Tax Expense (Benefit) |
$2,903,292
Trailing 12 months · 30 Jun 2023
|
-100% |
| Inventory, Net |
$2,348,133
Period-end balance · 30 Jun 2023
|
+86% |
| Operating Income (Loss) |
$427,504
Reported period · 30 Jun 2023
|
-109% |
| Preferred Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Jun 2023
|
0% |
| Preferred Stock, Shares Authorized |
5,000,000
Period-end balance · 30 Jun 2023
|
0% |
| Preferred Stock, Shares Issued |
0
Period-end balance · 30 Jun 2023
|
|
| Preferred Stock, Shares Outstanding |
0
Period-end balance · 30 Jun 2023
|
|
| Property, Plant and Equipment, Gross |
$1,921,421
Period-end balance · 30 Jun 2023
|
+18% |
| Property, Plant and Equipment, Net |
$617,138
Period-end balance · 30 Jun 2023
|
+27% |
| Retained Earnings (Accumulated Deficit) |
$8,068,592
Period-end balance · 30 Jun 2023
|
+747% |
| Stockholders' Equity Attributable to Parent |
$14,855,940
Period-end balance · 30 Jun 2023
|
+684% |
| Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
$15,264,970
Period-end balance · 30 Jun 2023
|
+654% |
Comparisons, sources and research notes
Sources and sharing
Tengjun Biotechnology Corp. Financial Facts
- Context
- Latest metrics period: Q2 2023
- Latest reported value
- NetIncomeLoss YoY -112%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q2 2023
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q2 2023.
- Most recent SEC facts end date on this page: 10 Aug 2023.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for Tengjun Biotechnology Corp.
Latest financial period: Q2 2023. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
15 Aug 2023
Page type
Company facts
Latest period
Q2 2023
SEC-backed company facts were refreshed from filings filed on 15 Aug 2023.
Benchmark Context
How NetIncomeLoss YoY compares
NetIncomeLoss YoY does not yet have enough prior-period data for a historical comparison on this page.
Compared with
Compared with Tengjun Biotechnology Corp.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
NetIncomeLoss YoY already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q2 2023.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Net Income on this page
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Filing notes and source
Key facts
- Tengjun Biotechnology Corp. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q2 2023.
- Headline metric: NetIncomeLoss YoY -112%.
Change
- Comparable YoY change is unavailable for this metric.
- Most recent SEC facts end date: 10 Aug 2023.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2023-08-10) highlights NetIncomeLoss YoY -111.6%.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
No market comparison
Medium confidence
Fair value per share
$1.10
Market price
n/a
PEG ratio
n/a
Enterprise value
$110.18M
Equity value
$110.18M
DCF fair value scenarios
Bear
$0.8208
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Base
$1.10
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Bull
$1.54
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Market price market EV / SEC revenue
Market enterprise value is unavailable
EV/EBITDA
n/a
Market price market EV / SEC EBITDA
Market enterprise value is unavailable
P/E
n/a
Market price market price / SEC EPS
Market cap is unavailable
P/S
n/a
Market price market cap / SEC revenue
Market cap is unavailable
P/B
n/a
Market price market cap / SEC equity
Market cap is unavailable
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $7.57M
- Trailing SEC FCF
- Reported FCF
- $7.57M
- Net income
- $453.1K
- EBITDA
- $157.5K
- Cash
- $2.8K
- Debt
- n/a
- Equity
- $14.86M
- Shares
- 100,187,364
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Ticker missing for issuer
- Debt missing: equity value treats debt as 0
- Peg unavailable: market price is missing
Compare This Company Through SEC-backed Metrics
Use these links to compare Tengjun Biotechnology Corp. against other SEC filers on the same metric, then verify the company history from the paired facts page.
NetIncomeLoss YoY
Latest value: -112%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
0.0/100
Weak Confidence low
Financial Health
Strengths
No strong signals yet.
Watchpoints
NetIncomeLoss YoY
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first